Mandelic Acid, Methyl Ester

Mandelic Acid, Methyl Ester

SCHEMBL186900

COC(=O)[C@H](O)c1ccccc1

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.67
LMNA P02545 6/20 0.58
MAPK1 P28482 1/20 0.58
CES2 O00748 1/20 0.52
CES1 P23141 1/20 0.52
HPGD P15428 1/20 0.52
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
HSD17B10 Q99714 1/20 0.49
MEN1 O00255 2/20 0.49
PTGS1 P23219 1/20 0.49
PTGS2 P35354 1/20 0.49
ALDH1A1 P00352 1/20 0.49
CHRM2 P08172 2/20 0.47
CHRM1 P11229 2/20 0.47
CHRM4 P08173 1/20 0.47
CHRM5 P08912 1/20 0.47
CHRM3 P20309 1/20 0.47
BLM P54132 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mandelic Acid, Methyl Ester SCHEMBL28228867 1.00 KMT2A (0.67) KMT2ALMNAMAPK1CES2CES1
Mandelic Acid, Methyl Ester SCHEMBL186899 1.00 KMT2A (0.67) KMT2ALMNAMAPK1CES2CES1
Mandelic Acid, Methyl Ester SCHEMBL186898 1.00 KMT2A (0.67) KMT2ALMNAMAPK1CES2CES1
Mandelic Acid, Methyl Ester SCHEMBL7701656 0.98 KMT2A (0.64) KMT2ALMNAMAPK1CES2CES1
Mandelic Acid, Methyl Ester SCHEMBL27579970 0.98 KMT2A (0.64) KMT2ALMNAMAPK1CES2CES1
Mandelic Acid, Methyl Ester SCHEMBL8082961 0.98 KMT2A (0.64) KMT2ALMNAMAPK1CES2CES1
Mandelic Acid, Methyl Ester SCHEMBL7512539 0.96 KMT2A (0.62) KMT2ALMNAMAPK1CES2CES1
Mandelic Acid, Methyl Ester SCHEMBL29214409 0.94 KMT2A (0.60) KMT2ALMNAMAPK1CES2CES1
Mandelic Acid, Methyl Ester SCHEMBL30951860 0.92 KMT2A (0.63) KMT2ALMNAMAPK1CES2CES1
SCHEMBL6240606 0.92 KMT2A (0.58) KMT2ALMNAMAPK1CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 771 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025125052-A1 METHOD FOR ACTIVATING A HETEROGENEOUS CATALYST IN THE PRESENCE OF A MULTIFUNCTIONAL ACID COMPOUND IFP Energies Nouvelles (FR) 2025-06-19 WO claimed
US-12319952-B2 Method for enzymatic resolution of chiral substances SOUTH CHINA UNIVERSITY OF TECHNOLOGY (CN) 2025-06-03 US claimed
CN-118702633-A Preparation method of drug chlorinated intermediate for preventing cytomegalovirus infection 台州职业技术学院 2024-09-27 CN claimed
CN-115583867-B Resolution method of L-2-aminopropanol 湖南复瑞生物医药技术有限责任公司 2024-08-02 CN claimed
WO-2024145663-A2 SALT FORMS OF R-MDMA AND METHODS USING THE SAME EMPATHBIO, INC. (US) 2024-07-04 WO claimed
CN-118218027-A Application of polydentate ligand/ruthenium catalyst and method for preparing diol compound by hydrogenation reaction of alpha-hydroxy ester 郑州大学 2024-06-21 CN claimed
CN-113862117-B Device and method for separating chiral substances by multi-liquid-phase system continuous enzyme method 华南理工大学 2024-03-12 CN claimed
CN-114315866-B Synthesis method of levamisole hydrochloride 烟台药物研究所 2023-10-31 CN claimed
CN-116786012-A Preparation method of chemicals and stirring device capable of sectionally blanking 江西科苑生物股份有限公司 2023-09-22 CN claimed
US-11760750-B1 Process for preparing levoketoconazole NURAY CHEMICALS PRIVATE LIMITED (IN) 2023-09-19 US claimed
CN-1278076-A Agent for lowering dependence of substrate WAKO PURE CHEM IND LTD (JP) 2000-12-27 CN claimed
EP-1059563-A1 Agent for reducing substrate dependence of resist Wako Pure Chemical Industries, Ltd. (JP) 2000-12-13 EP claimed
EP-0948490-A1 PROCESS FOR THE PREPARATION OF 2-IMINO-5-PHENYL-4-OXAZOLIDINONE AND ITS INTERMEDIATES Abbott Laboratories (US) 1999-10-13 EP claimed
WO-1999048894-A1 NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION ONCOPHARM CORPORATION (US) 1999-09-30 WO claimed
WO-1998022450-A1 PROCESS FOR THE PREPARATION OF 2-IMINO-5-PHENYL-4-OXAZOLIDINONE AND ITS INTERMEDIATES ABBOTT LABORATORIES (US) 1998-05-28 WO claimed
US-5677463-A Process for the preparation of 2-imino-5-phenyl-4 oxazolidinone and its intermediates ABBOTT LABORATORIES (US) 1997-10-14 US claimed
US-5332522-A Thermotropic chiral nematic liquid crystalline copolymers THE UNIVERSITY OF ROCHESTER (US) 1994-07-26 US claimed
US-5243070-A PROCESS FOR RESOLUTION OF RACEMATES OF 2,2-DIMETHYLCYCLOPROPANECARBOXYLIC ACID LONZA LTD. (CH) 1993-09-07 US claimed
EP-0342804-B1 TRIOXANE COMPOSITION AND INSECT-PROOFING AGENT MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1992-12-02 EP claimed
EP-0342804-A2 Trioxane composition and insect-proofing agent MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1989-11-23 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11760750-B1 Process for preparing levoketoconazole KHK, KYAT3, PLK3 KMT2A 1550/4885LMNA 1990/4885MAPK1 1537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.